Sipuleucel-T: Autologous cellular immunotherapy for men with asymptomatic or minimally symptomatic metastatic castrate resistant prostate cancer

Journal of Cancer

Volumn 2, Issue 1, 2011, Pages 357-359

  Sims, Robert B ^a  

^a Dendreon   (United States)

Author keywords

Metastatic castrate resistant prostate cancer (mCRPC); Sipuleucel T

Indexed keywords

GAMMA INTERFERON; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 10; INTERLEUKIN 12P70; INTERLEUKIN 17; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 23; INTERLEUKIN 4; INTERLEUKIN 5; SIPULEUCEL T; TESTOSTERONE; TUMOR NECROSIS FACTOR ALPHA;

ANTIGEN PRESENTING CELL; ARTICLE; CANCER GROWTH; CANCER SURVIVAL; CASTRATED MALE; CELL ACTIVATION; CELL PROLIFERATION; CHILL; FEVER; FLU LIKE SYNDROME; GROIN PAIN; HEADACHE; HUMAN; HYPERHIDROSIS; HYPERTENSION; IMMUNE RESPONSE; MALE; METASTASIS; MYALGIA; OVERALL SURVIVAL; PAIN; PERIPHERAL BLOOD MONONUCLEAR CELL; PHASE 3 CLINICAL TRIAL (TOPIC); PROGNOSIS; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL (TOPIC); T LYMPHOCYTE; UPREGULATION;

EID: 83055188998     PISSN: None     EISSN: 18379664     Source Type: Journal    
DOI: 10.7150/jca.2.357     Document Type: Article

References (7)

1. Burch PA, Breen JK, Buckner JC, et al. Priming tissue-specific cellular immunity in a phase I trial of autologous dendritic cells for prostate cancer. Clin Cancer Res. 2000 Jun;6(6):2175-82.
2. Small EJ, Fratesi P, Reese DM, et al. Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells. J Clin Oncol. 2000 Dec 1;18(23):3894-903.
3. Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010;363(5):411-22.
4. Small EJ, Schellhammer PF, Higano CS, et al. Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J Clin Oncol. 2006 Jul 1;24(19):3089-94.
5. Higano CS, Schellhammer PF, Small EJ, et al. Integrated data from 2 randomized, double-blind, placebo-controlled, Phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer. Cancer. 2009 Aug 15;115(16):3670-9.
6. Sheikh NA, Jones LA. CD54 is a surrogate marker of antigen presenting cell activation. Cancer Immunol Immunother. 2008 Sep;57(9):1381-90.
7. Sheikh NA, dela Rosa C, Frohlich MW, et al. Sipuleucel-T treatment results in sequential ex vivo activation of APCs and T cells during the culture step - evidence for in vivo immunological priming. Washington DC: Annual Meeting of the American Association for Cancer Research; 2010.